| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
PADPRPeroxynitritePARPPosttranslational protein modification| 1 | 2007 | Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. | 
| + | - | nl | Cardiovasc Drug Rev 25(3):235-60 (2007) |
| 2 | 2002 | The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. |
| + | - | nl | Pharmacol Rev 54(3):375-429 (2002) |
| 3 | 2006 | Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? |
| + | - | nl | Microbiol Mol Biol Rev 70(3):789-829 (2006) |
| 4 | 2007 | Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. |
| + | - | nl | Clin Cancer Res 13(21):6252-6 (2007) |
| 5 | 2007 | Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. |
| + | - | nl | Clin Cancer Res 13(5):1383-8 (2007) |
| 6 | 2007 | PolyADP-ribosylation and cancer. |
| + | - | nl | Cancer Sci 98(10):1528-35 (2007) |
| 7 | 2008 | Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. |
| + | - | nl | Am J Pathol 173(1):2-13 (2008) |
| 8 | 2005 | Poly(ADP-ribose). The most elaborate metabolite of NAD+. |
| + | - | nl | FEBS J 272(18):4576-89 (2005) |
| 9 | 2005 | Physiological relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins. |
| + | - | nl | FEBS J 272(18):4565-75 (2005) |
| 10 | 2010 | Targeting poly(ADP-ribose) polymerase activity for cancer therapy. |
| + | - | nl | Cell Mol Life Sci 67(21):3649-62 (2010) |
| 11 | 2008 | The expanding field of poly(ADP-ribosyl)ation reactions. 'Protein Modifications: Beyond the Usual Suspects' Review Series. |
| + | - | nl | EMBO Rep 9(11):1094-100 (2008) |
